420 with CNW — Swiss Capital to Run Pilot Program of Marijuana Legalization
In an experiment to evaluate the financial and social advantages of controlling marijuana, the Swiss regime has authorized its intentions to end the criminalization of the trade and use of marijuana in Zurich. Beginning this summer, some 2,100 Zurich residents will be allowed to purchase the medicine in predetermined amounts for individual use from drugstores, social clubs and medical facilities throughout the city.
As a requirement for the research carried out in partnership with Zurich University, those participating will respond to survey questions every six months regarding their consumption patterns and health impacts. The experiment’s ultimate goal is to ascertain the circumstances wherein Switzerland’s permission for marijuana use can be consistent with enhancing private and public wellness and safety, according to the leaders of the study.
In the following year, the evidence gathered from the experiment will be made public in bits and pieces. The goal is to gather solid real-world data that will aid in the creation of new marijuana regulations.
This decision was made at a time when other regions of Europe are reviewing their cannabis laws in reaction to broader shifts in worldwide drug laws. In the weeks to come, Germany, the continent’s largest economy, anticipates introducing a bill legalizing cannabis use and sales, making it the first European Union nation to allow for the drug’s widespread commercial sale. The Czech Republic and nearby Luxembourg also recently introduced measures to allow marijuana for adult use. Small quantities of the substance for personal use are not considered illegal in Spain, Italy and Australia.
In 2021, Malta, the smallest EU country, became the first nation in the union to legalize marijuana for personal use and to allow the creation of individual marijuana clubs where users can cultivate and exchange the drug. For the past 10 years, efforts have been made to end the prohibition of the substance in Uruguay, Canada and most recently, Thailand.
Residents of Zurich are welcome to register if they’re willing to participate in the experiment. Participants must be active marijuana users who are of consenting age, do not have any chronic medical issues, and aren’t fully engaged as commercial drivers.
Primary-care surveys indicate that roughly one-third of consenting Swiss citizens have reportedly tried marijuana. Approximately 13,000 citizens of Zurich are frequent users.
In the upcoming months, more investigations are also anticipated in Bern, Thun, Basel, Olten, Geneva, Winterthur and Biel, with support from the public and academic sectors.
While these efforts abroad are ongoing to test the waters of cannabis legalization, several companies in the United States, such as India Globalization Capital Inc. (NYSE American: IGC), are doing their own research aimed at developing a number of formulations that are effective against health conditions such as chronic pain and others.
NOTE TO INVESTORS: The latest news and updates relating to India Globalization Capital Inc. (NYSE American: IGC) are available in the company’s newsroom at https://cnw.fm/IGC
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer
In an experiment to evaluate the financial and social advantages of controlling marijuana, the Swiss regime has authorized its intentions to end the criminalization of the trade and use of marijuana in Zurich. Beginning this summer, some 2,100 Zurich residents will be allowed to purchase the medicine in predetermined amounts for individual use from drugstores, social clubs and medical facilities throughout the city.
As a requirement for the research carried out in partnership with Zurich University, those participating will respond to survey questions every six months regarding their consumption patterns and health impacts. The experiment’s ultimate goal is to ascertain the circumstances wherein Switzerland’s permission for marijuana use can be consistent with enhancing private and public wellness and safety, according to the leaders of the study.
In the following year, the evidence gathered from the experiment will be made public in bits and pieces. The goal is to gather solid real-world data that will aid in the creation of new marijuana regulations.
This decision was made at a time when other regions of Europe are reviewing their cannabis laws in reaction to broader shifts in worldwide drug laws. In the weeks to come, Germany, the continent’s largest economy, anticipates introducing a bill legalizing cannabis use and sales, making it the first European Union nation to allow for the drug’s widespread commercial sale. The Czech Republic and nearby Luxembourg also recently introduced measures to allow marijuana for adult use. Small quantities of the substance for personal use are not considered illegal in Spain, Italy and Australia.
In 2021, Malta, the smallest EU country, became the first nation in the union to legalize marijuana for personal use and to allow the creation of individual marijuana clubs where users can cultivate and exchange the drug. For the past 10 years, efforts have been made to end the prohibition of the substance in Uruguay, Canada and most recently, Thailand.
Residents of Zurich are welcome to register if they’re willing to participate in the experiment. Participants must be active marijuana users who are of consenting age, do not have any chronic medical issues, and aren’t fully engaged as commercial drivers.
Primary-care surveys indicate that roughly one-third of consenting Swiss citizens have reportedly tried marijuana. Approximately 13,000 citizens of Zurich are frequent users.
In the upcoming months, more investigations are also anticipated in Bern, Thun, Basel, Olten, Geneva, Winterthur and Biel, with support from the public and academic sectors.
While these efforts abroad are ongoing to test the waters of cannabis legalization, several companies in the United States, such as India Globalization Capital Inc. (NYSE American: IGC), are doing their own research aimed at developing a number of formulations that are effective against health conditions such as chronic pain and others.
NOTE TO INVESTORS: The latest news and updates relating to India Globalization Capital Inc. (NYSE American: IGC) are available in the company’s newsroom at https://cnw.fm/IGC
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer
